celecoxib and Angiogenesis, Pathologic studies

Research Excerpts

Excerpt	Relevance	Reference
"A total of nine patients with malignant glioma, postoperatively presenting with a Karnofsky performance score (KPS) below 70, were treated with standalone metronomic low-dose chemotherapy with temozolomide and celecoxib (cyclo-oxygenase-2 inhibitor)."	7.81	Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard Treatment. ( Brawanski, KR; Freyschlag, CF; Grams, AE; Kerschbaumer, J; Nowosielski, M; Petr, O; Pinggera, D; Schmidt, FA; Seiz, M; Thomé, C; Tuettenberg, J, 2015)
"To evaluate the effects of celecoxib and rosiglitazone on the implantation and growth of endometriotic-like lesions in a murine model of endometriosis."	7.77	The inhibitory effect of celecoxib and rosiglitazone on experimental endometriosis. ( Barañao, RI; Bilotas, M; Meresman, G; Olivares, C; Ricci, A, 2011)
"Toward improved glioblastoma multiforme treatment, we determined whether celecoxib, a selective cyclooxygenase (COX)-2 inhibitor, could enhance glioblastoma radiosensitivity by inducing tumor necrosis and inhibiting tumor angiogenesis."	7.74	Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis. ( Cheah, ES; Kang, KB; Moore, XL; Wang, TT; Wong, MC; Woon, CT; Zhu, C, 2007)
" Celecoxib treatment inhibited COX-2 activity, indicated by prostaglandin E2 secretion, and caused significant growth arrest in both breast cancer cell lines."	7.73	Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. ( Basu, GD; Gendler, SJ; Mukherjee, P; Pathangey, LB; Tinder, TL, 2005)
" This prompted us to investigate the chemopreventive potential of celecoxib, a selective COX-2 inhibitor, against prostate carcinogenesis in a transgenic adenocarcinoma of the mouse prostate (TRAMP) model."	7.72	Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. ( Adhami, VM; Fu, P; Gupta, S; Hafeli, UO; Lewin, JS; MacLennan, GT; Mukhtar, H; Subbarayan, M, 2004)
" We undertook a retrospective study comparing the incidences of hand-foot syndrome in 67 patients with metastatic colorectal cancer who took capecitabine (Xeloda) with or without celecoxib."	7.71	Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. ( Ayers, GD; Lin, E; Morris, JS, 2002)
"In the comparison of carcinogenesis, the percentage of normal tissue (i."	5.40	Combinational chemoprevention effect of celecoxib and an oral antiangiogenic LHD4 on colorectal carcinogenesis in mice. ( Alam, F; Byun, Y; Chung, SW; Jeon, OC; Kim, JY; Kim, SY; Park, J; Son, WC, 2014)
"Rheumatoid arthritis is a chronic inflammatory disease characterized by overproduction of inflammatory mediators along with undermined oxidative defensive mechanisms."	5.40	Evening primrose oil and celecoxib inhibited pathological angiogenesis, inflammation, and oxidative stress in adjuvant-induced arthritis: novel role of angiopoietin-1. ( El-Azab, MF; El-Sayed, RM; Moustafa, YM, 2014)
"Refractoriness of invasive breast cancer is closely related with the vasculogenic mimicry (VM) channels, which exhibit highly drug resistance to conventional chemotherapies."	5.40	Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer. ( Ju, RJ; Li, XT; Li, XY; Liu, L; Lu, WL; Shi, JF; Sun, MG; Zeng, F; Zhang, CX; Zhao, WY; Zhou, J, 2014)
"In this study, the role of inflammation in traumatic heterotopic ossification around temporomandibular joint (THO-TMJ), as well as the preventive and treatment effect of celecoxib in THO-TMJ both in vivo and in vitro were explored."	3.96	The effect of celecoxib in traumatic heterotopic ossification around temporomandibular joint in mice. ( Chen, L; Chen, Q; Dai, J; Fang, B; Ouyang, N; Shen, G; Zhao, Y, 2020)
"A total of nine patients with malignant glioma, postoperatively presenting with a Karnofsky performance score (KPS) below 70, were treated with standalone metronomic low-dose chemotherapy with temozolomide and celecoxib (cyclo-oxygenase-2 inhibitor)."	3.81	Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard Treatment. ( Brawanski, KR; Freyschlag, CF; Grams, AE; Kerschbaumer, J; Nowosielski, M; Petr, O; Pinggera, D; Schmidt, FA; Seiz, M; Thomé, C; Tuettenberg, J, 2015)
"Tamoxifen (TAM) is widely used in the chemotherapy of breast cancer and as a preventive agent against recurrence after surgery."	3.79	Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling. ( Das, S; Dey, KK; Kumar, BN; Mandal, M; Mazumdar, A; Parekh, A; Rajput, S, 2013)
"To validate the efficacy of an innovative multimodality therapy with transcatheter arterial embolization (TAE) plus octreotide and celecoxib in reducing neoangiogenesis and prolonging the survival of rabbits with hepatocellular carcinoma."	3.79	Transcatheter arterial embolization followed by octreotide and celecoxib synergistically prolongs survival of rabbits with hepatic VX2 allografts. ( Fu, P; Gao, JH; Huang, ZY; Li, X; Tang, CW; Tong, H; Wen, FQ; Wen, SL; Zhang, CL, 2013)
"Celecoxib prevents lung metastasis in a murine model of Ewing sarcoma with no effect on tumor size or neovascularization."	3.77	Selective inhibition of cyclooxygenase-2 suppresses metastatic disease without affecting primary tumor growth in a murine model of Ewing sarcoma. ( Edelman, M; Gendy, AS; Glick, RD; Lipskar, A; Soffer, SZ; Steinberg, BM, 2011)
"To evaluate the effects of celecoxib and rosiglitazone on the implantation and growth of endometriotic-like lesions in a murine model of endometriosis."	3.77	The inhibitory effect of celecoxib and rosiglitazone on experimental endometriosis. ( Barañao, RI; Bilotas, M; Meresman, G; Olivares, C; Ricci, A, 2011)
"Morphine and its congener opioids are the main therapy for severe pain in cancer."	3.74	COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. ( Farooqui, M; Griffin, RJ; Gupta, K; Li, Y; Poonawala, T; Rogers, T; Song, CW, 2007)
"Toward improved glioblastoma multiforme treatment, we determined whether celecoxib, a selective cyclooxygenase (COX)-2 inhibitor, could enhance glioblastoma radiosensitivity by inducing tumor necrosis and inhibiting tumor angiogenesis."	3.74	Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis. ( Cheah, ES; Kang, KB; Moore, XL; Wang, TT; Wong, MC; Woon, CT; Zhu, C, 2007)
" A human breast cancer cell line, MDA-MB-231, was implanted in 30 female homozygotous athymic rats that were alternately assigned to either a drug treatment group that received celecoxib on a daily basis for 7 days or a control group that received saline."	3.74	MR monitoring of cyclooxygenase-2 inhibition of angiogenesis in a human breast cancer model in rats. ( Brasch, RC; Floyd, E; Fournier, LS; Fu, Y; Lucidi, V; Miller, T; Novikov, V; Shames, DM, 2007)
"To determine whether COX-2 regulates vascular channel formation, we assessed whether treatment with celecoxib (a selective COX-2 inhibitor) or silencing COX-2 synthesis by siRNA inhibits vascular channel formation by breast cancer cell lines."	3.73	A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells. ( Basu, GD; Conley, CR; Liang, WS; Mukherjee, P; Pockaj, BA; Stephan, DA; Wegener, LT, 2006)
" Celecoxib treatment inhibited COX-2 activity, indicated by prostaglandin E2 secretion, and caused significant growth arrest in both breast cancer cell lines."	3.73	Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. ( Basu, GD; Gendler, SJ; Mukherjee, P; Pathangey, LB; Tinder, TL, 2005)
" Here we characterized the effects of non-selective (indomethacin) and selective (NS398, celecoxib) cyclooxygenase inhibitors on parameters of angiogenesis in human pancreatic adenocarcinoma cells."	3.72	Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts. ( Davis, DW; Ellis, LM; Khanbolooki, S; Lashinger, LM; McConkey, DJ; Nawrocki, S; Raut, CP; Xiong, H, 2004)
" This prompted us to investigate the chemopreventive potential of celecoxib, a selective COX-2 inhibitor, against prostate carcinogenesis in a transgenic adenocarcinoma of the mouse prostate (TRAMP) model."	3.72	Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. ( Adhami, VM; Fu, P; Gupta, S; Hafeli, UO; Lewin, JS; MacLennan, GT; Mukhtar, H; Subbarayan, M, 2004)
" We undertook a retrospective study comparing the incidences of hand-foot syndrome in 67 patients with metastatic colorectal cancer who took capecitabine (Xeloda) with or without celecoxib."	3.71	Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. ( Ayers, GD; Lin, E; Morris, JS, 2002)
"Preclinical models show that an antiangiogenic regimen at low-dose daily (metronomic) dosing may be effective against chemotherapy-resistant tumors."	2.79	A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. ( Allen, JC; Bendel, AE; Campigotto, F; Chi, SN; Chordas, CA; Comito, MA; Goldman, S; Hubbs, SM; Isakoff, MS; Khatib, ZA; Kieran, MW; Kondrat, L; Manley, PE; Neuberg, DS; Pan, WJ; Pietrantonio, JB; Robison, NJ; Rubin, JB; Turner, CD; Werger, AM; Zimmerman, MA, 2014)
"Celecoxib was given at 400 mg twice daily."	2.73	Biologic markers of angiogenesis: circulating endothelial cells in patients with advanced malignancies treated on phase I protocol with metronomic chemotherapy and celecoxib. ( Carroll, M; Frankel, P; Ruel, C; Smith-Powell, L; Synold, TW; Twardowski, PW; VanBalgooy, J, 2008)
"Continuous dosing of the combination of capecitabine and celecoxib was well tolerated, produced antiangiogenic effects, and has antitumor activity."	2.73	Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study. ( Arends, J; Drevs, J; Frost, A; Häring, B; Hennig, J; Medinger, M; Mross, K; Steinbild, S; Strecker, R; Unger, C, 2007)
"Fifty nine gastric cancer patients were randomly divided into two groups: Surgery group (n = 22), in which patients underwent surgical resection after diagnosis, and Celecoxib + Surgery group (n = 37), in which patients received oral Celecoxib 200 mg twice daily for 7 days before curative resection."	2.73	Effect of celecoxib on E-cadherin, VEGF, Microvessel density and apoptosis in gastric cancer. ( Honghua, L; Ning, C; Qiao, L; Ran, J; Tang, C; Wu, J; Xingwen, L; Zhou, Y, 2007)
"Fifty nine gastric cancer patients were randomly divided into 2 groups: celecoxib group (n = 37) and control group (n = 22)."	2.73	[Celecoxib induces apoptosis and inhibits angiogenesis in gastric cancer]. ( Lu, H; Lu, JR; Ran, JT; Tang, CW; Wu, J; Yang, GD; Zhou, YN, 2008)
"Paclitaxel has antiangiogenic properties, but the mechanisms for the enhanced sensitivity of endothelial cells (ECs) to this drug are not established."	2.71	Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition. ( Bubley, GJ; He, X; Jayaram, DR; Merchan, JR; Sukhatme, VP; Supko, JG, 2005)
"Serum levels of squamous cell carcinoma antigen and the proliferative potential and subsets of peripheral T cells before and after celecoxib treatment were also analyzed."	2.71	Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study. ( Battaglia, A; Ferrandina, G; Gessi, M; Lauriola, L; Legge, F; Navarra, P; Ranelletti, FO; Salutari, V; Scambia, G; Testa, AC; Tringali, G; Werner, U, 2003)
"Celecoxib is an NSAID that was developed as a selective inhibitor of COX-2 and approved by the FDA for the treatment of various forms of arthritis and the management of acute or chronic pain."	2.44	Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs. ( Chen, TC; Hofman, FM; Louie, SG; Petasis, NA; Schönthal, AH, 2008)
"COX-2 is expressed in all stages of cancer, and in several cancers its overexpression is associated with poor prognosis."	2.42	Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? ( Choy, H; Milas, L, 2003)
" Epidemiologic data showed that chronic intake of traditional nonsteroidal anti-inflammatory drugs (NSAIDs) could reduce the incidence of colorectal cancer."	2.42	Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications. ( Chen, BD; Chou, TH; Chu, AJ, 2004)
"Inflammation is a potent promoter of tumor metastasis."	1.42	Lipopolysaccharide induces inflammation and facilitates lung metastasis in a breast cancer model via the prostaglandin E2-EP2 pathway. ( Bi, Y; Han, M; Jiang, M; Li, S; Xu, J; Xu, X, 2015)
"Murine prostate cancer cells (RM9) were intravenously injected and lung metastasis was estimated by counting colonies in the lungs."	1.40	Roles of microsomal prostaglandin E synthase-1 in lung metastasis formation in prostate cancer RM9 cells. ( Akira, S; Amano, H; Ikeda, M; Iwamura, M; Kitasato, H; Majima, M; Satoh, T; Tabata, K; Takahashi, R, 2014)
"Rheumatoid arthritis is a chronic inflammatory disease characterized by overproduction of inflammatory mediators along with undermined oxidative defensive mechanisms."	1.40	Evening primrose oil and celecoxib inhibited pathological angiogenesis, inflammation, and oxidative stress in adjuvant-induced arthritis: novel role of angiopoietin-1. ( El-Azab, MF; El-Sayed, RM; Moustafa, YM, 2014)
"In the comparison of carcinogenesis, the percentage of normal tissue (i."	1.40	Combinational chemoprevention effect of celecoxib and an oral antiangiogenic LHD4 on colorectal carcinogenesis in mice. ( Alam, F; Byun, Y; Chung, SW; Jeon, OC; Kim, JY; Kim, SY; Park, J; Son, WC, 2014)
" As long-term use of COX-2 inhibitors (COX-2i) can promote thrombo-embolic events, we tested an alternative target, prostaglandin E2 receptor EP4 subtype (EP4), downstream of COX-2."	1.40	Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions. ( Girish, GV; Lala, PK; Liu, L; Majumder, M; Xin, X, 2014)
"Refractoriness of invasive breast cancer is closely related with the vasculogenic mimicry (VM) channels, which exhibit highly drug resistance to conventional chemotherapies."	1.40	Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer. ( Ju, RJ; Li, XT; Li, XY; Liu, L; Lu, WL; Shi, JF; Sun, MG; Zeng, F; Zhang, CX; Zhao, WY; Zhou, J, 2014)
"Treatment with celecoxib had effects on inflammation response and reduced cancer metastasis."	1.39	Primary tumor regulates the pulmonary microenvironment in melanoma carcinoma model and facilitates lung metastasis. ( Bi, Y; Han, M; Jia, J; Jiang, M; Liu, Q; Xu, J; Xu, X, 2013)
"Treatment with celecoxib, a selective COX-2 inhibitor, caused a 45% reduction in mammary PGE(2) levels, attenuated the influx of mast cells and reduced vascularization in Tg glands."	1.38	Transgenic insulin-like growth factor-1 stimulates activation of COX-2 signaling in mammary glands. ( Berton, TR; Conti, CJ; Digiovanni, J; Fischer, SM; Fuchs-Young, R; Kiguchi, K; Lambertz, I; Rundhaug, JE; Shirley, SH; Tian, J, 2012)
"However, results from pancreatic cancer trials of their inhibitors were disappointing."	1.36	Vascular endothelial growth factor and not cyclooxygenase 2 promotes endothelial cell viability in the pancreatic tumor microenvironment. ( Conlon, KC; Geary, M; Manahan, E; McKeown, C; McMillan, H; Murphy, JF; Rogers, A; Toomey, DP, 2010)
"Gliomatosis cerebri is a rare primary cerebral tumour entity characterized by diffuse infiltrative growth patterns representing a WHO grade III malignancy."	1.35	First experiences with low-dose anti-angiogenic treatment in gliomatosis cerebri with signs of angiogenic activity. ( Brockmann, MA; Hermes, P; Kohlhof, P; Neumaier-Probst, E; Schmieder, K; Seiz, M; Tuettenberg, J; Vajkoczy, P; VON Deimling, A, 2009)
"Celecoxib could inhibit tumor growth and enhance the antitumor effects of oxaliplatin through their synergistic role in inhibiting different targets."	1.35	Synergistic inhibition effect of tumor growth by using celecoxib in combination with oxaliplatin. ( Bian, H; Cai, J; Gui, L; Zhao, F; Zhao, S, 2009)
" However, the tumors administered with a initial dose of CX at 24-h post-PDT had no tumor control."	1.33	Anti-angiogenic effects of Hypericin-photodynamic therapy in combination with Celebrex in the treatment of human nasopharyngeal carcinoma. ( Olivo, M; Soo, KC; Yee, KK, 2005)
"Treatment with Celecoxib reduced both microvessel density and tumor growth."	1.33	The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice. ( Abdollahi, A; Ewerbeck, V; Gebhard, MM; Huber, PE; Klenke, FM; Sckell, A, 2006)
"In the present study, we used a pancreatic cancer model to determine the role of Sp1 in the antitumor activity of celecoxib."	1.32	Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. ( Abbruzzese, JL; He, Y; Wang, L; Wei, D; Xie, K; Xiong, HQ, 2004)
"Although all hamsters developed squamous cell carcinoma, the onset of tumor formation was delayed in a dose-dependent manner."	1.32	Increased expression of cyclooxygenase (COX)-2 in DMBA-induced hamster cheek pouch carcinogenesis and chemopreventive effect of a selective COX-2 inhibitor celecoxib. ( Hashitani, S; Manno, Y; Nishimura, N; Noguchi, K; Sakurai, K; Takaoka, K; Urade, M, 2004)
"Celecoxib is a newly developed cyclo-oxygenase (COX)-2 inhibitor with significantly less toxicity."	1.31	Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell. ( Fuentes, CF; Shapshay, SM; Wang, Z, 2002)

Research

Studies (94)

Authors

Clinical Trials (6)

Trial Overview

Trial Outcomes

27-Week Overall Survival

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	47 (50.00)	29.6817
2010's	44 (46.81)	24.3611
2020's	3 (3.19)	2.80

Authors	Studies
Dakshanamurthy, S	1
Issa, NT	1
Assefnia, S	1
Seshasayee, A	1
Peters, OJ	1
Madhavan, S	1
Uren, A	1
Brown, ML	1
Byers, SW	1
Ouyang, N	1
Zhao, Y	1
Chen, Q	1
Chen, L	1
Fang, B	1
Dai, J	1
Shen, G	2
Wang, L	5
Wu, H	1
Xiong, L	1
Liu, X	2
Yang, N	1
Luo, L	1
Qin, T	1
Zhu, X	1
Shen, Z	1
Jing, H	1
Chen, J	1
Qadir, A	1
Wahid, M	1
Asif, M	1
Roome, T	1
Zhang, B	2
Jin, K	1
Jiang, T	1
Shen, S	1
Luo, Z	1
Tuo, Y	1
Hu, Y	1
Pang, Z	1
Gungor, H	2
Ilhan, N	2
Eroksuz, H	2
Yoysungnoen, B	1
Bhattarakosol, O	1
Changtam, C	1
Patumraj, S	1
Fikry, EM	1
Gad, AM	1
Eid, AH	1
Arab, HH	1
Majumder, M	2
Xin, X	2
Lala, PK	2
Kumar, BN	1
Rajput, S	1
Dey, KK	1
Parekh, A	1
Das, S	1
Mazumdar, A	1
Mandal, M	1
Gao, JH	3
Wen, SL	3
Yang, WJ	2
Lu, YY	2
Tong, H	3
Huang, ZY	3
Liu, ZX	1
Tang, CW	4
Robison, NJ	1
Campigotto, F	1
Chi, SN	1
Manley, PE	1
Turner, CD	1
Zimmerman, MA	1
Chordas, CA	1
Werger, AM	1
Allen, JC	1
Goldman, S	1
Rubin, JB	1
Isakoff, MS	1
Pan, WJ	1
Khatib, ZA	1
Comito, MA	1
Bendel, AE	1
Pietrantonio, JB	1
Kondrat, L	1
Hubbs, SM	1
Neuberg, DS	1
Kieran, MW	1
Takahashi, R	1
Amano, H	2
Satoh, T	1
Tabata, K	1
Ikeda, M	1
Kitasato, H	2
Akira, S	1
Iwamura, M	1
Majima, M	2
Searle, EJ	1
Illidge, TM	1
Stratford, IJ	1
Sui, W	1
Zhang, Y	1
Wang, Z	4
Jia, Q	1
Wu, L	1
Zhang, W	1
Xu, K	2
Shu, HK	2
El-Sayed, RM	1
Moustafa, YM	1
El-Azab, MF	1
Ju, RJ	1
Li, XT	1
Shi, JF	1
Li, XY	1
Sun, MG	1
Zeng, F	1
Zhou, J	1
Liu, L	3
Zhang, CX	1
Zhao, WY	1
Lu, WL	1
Girish, GV	1
Kim, JY	2
Alam, F	1
Chung, SW	2
Park, J	1
Jeon, OC	1
Kim, SY	2
Son, WC	1
Byun, Y	2
Rosas, C	1
Sinning, M	1
Ferreira, A	1
Fuenzalida, M	1
Lemus, D	1
Li, S	1
Xu, X	2
Jiang, M	2
Bi, Y	2
Xu, J	2
Han, M	2
Paprottka, PM	1
Roßpunt, S	1
Ingrisch, M	1
Cyran, CC	1
Nikolaou, K	1
Reiser, MF	1
Mack, B	1
Gires, O	1
Clevert, DA	1
Zengel, P	1
Valverde, A	1
Peñarando, J	1
Cañas, A	1
López-Sánchez, LM	1
Conde, F	1
Hernández, V	1
Peralbo, E	1
López-Pedrera, C	1
de la Haba-Rodríguez, J	1
Aranda, E	1
Rodríguez-Ariza, A	1
Kerschbaumer, J	1
Schmidt, FA	1
Grams, AE	1
Nowosielski, M	1
Pinggera, D	1
Brawanski, KR	1
Petr, O	1
Thomé, C	1
Tuettenberg, J	2
Seiz, M	2
Freyschlag, CF	1
Feng, S	1
Liu, R	1
Tang, SH	1
Tang, YM	1
Yang, JH	1
Xie, HQ	1
Gul, HF	1
Ghanghas, P	1
Jain, S	1
Rana, C	1
Sanyal, SN	2
Kassam, A	1
Mandel, K	1
Ran, JT	1
Zhou, YN	1
Lu, JR	1
Wu, J	2
Lu, H	1
Yang, GD	1
Maussang, D	1
Langemeijer, E	1
Fitzsimons, CP	1
Stigter-van Walsum, M	1
Dijkman, R	1
Borg, MK	1
Slinger, E	1
Schreiber, A	1
Michel, D	1
Tensen, CP	1
van Dongen, GA	1
Leurs, R	1
Smit, MJ	1
Zhao, S	1
Cai, J	1
Bian, H	1
Gui, L	1
Zhao, F	1
Zhang, LJ	1
Wang, SY	1
Huo, XH	1
Zhu, ZL	1
Chu, JK	1
Ma, JC	1
Cui, DS	1
Gu, P	1
Zhao, ZR	1
Wang, MW	1
Yu, J	1
Kohlhof, P	1
Brockmann, MA	1
Neumaier-Probst, E	1
Hermes, P	1
VON Deimling, A	1
Vajkoczy, P	1
Schmieder, K	1
Kim, CK	1
Joe, YA	1
Lee, SK	1
Kim, EK	1
O, E	1
Kim, HK	1
Oh, BJ	1
Hong, SH	1
Hong, YK	1
Fabbrini, P	1
Schilte, MN	1
Zareie, M	1
ter Wee, PM	1
Keuning, ED	1
Beelen, RH	1
van den Born, J	1
Ueno, T	1
Suzuki, T	1
Oikawa, A	1
Hosono, K	1
Kosaka, Y	1
Toda, M	1
Hayashi, I	1
Kato, T	1
Ito, Y	1
Sugimoto, Y	1
Narumiya, S	1
Okamoto, H	1
Toomey, DP	1
Manahan, E	1
McKeown, C	1
Rogers, A	1
McMillan, H	1
Geary, M	1
Conlon, KC	1
Murphy, JF	1
Gao, H	1
Klenke, FM	2
Abdollahi, A	2
Bischof, M	1
Gebhard, MM	2
Ewerbeck, V	2
Huber, PE	2
Sckell, A	2
Gendy, AS	1
Lipskar, A	1
Glick, RD	1
Steinberg, BM	1
Edelman, M	1
Soffer, SZ	1
Gravitz, L	1
Abedinpour, P	1
Baron, VT	1
Welsh, J	1
Borgström, P	1
Legge, F	2
Paglia, A	1
D'Asta, M	1
Fuoco, G	1
Scambia, G	2
Ferrandina, G	2
Olivares, C	1
Ricci, A	1
Bilotas, M	1
Barañao, RI	1
Meresman, G	1
Conde, N	1
Cruz, O	1
Albert, A	1
Mora, J	1
Tian, J	1
Lambertz, I	1
Berton, TR	1
Rundhaug, JE	1
Kiguchi, K	1
Shirley, SH	1
Digiovanni, J	1
Conti, CJ	1
Fischer, SM	1
Fuchs-Young, R	1
Scharovsky, OG	1
Matar, P	1
Rozados, VR	1
Rico, MJ	1
Zacarías Fluck, MF	1
Mainetti, LE	1
Fernández Zenóbi, MV	1
Roggero, EA	1
Gervasoni, SI	1
Rossa, A	1
Perroud, HA	1
Sánchez, AM	1
Celoria, GC	1
Font, MT	1
Vaish, V	1
Ninomiya, I	1
Nagai, N	1
Oyama, K	1
Hayashi, H	1
Tajima, H	1
Kitagawa, H	1
Fushida, S	1
Fujimura, T	1
Ohta, T	1
Liu, Q	1
Jia, J	1
Li, X	1
Zhang, CL	1
Wen, FQ	1
Fu, P	2
Ma, X	1
Li, Z	1
Gao, X	1
Wang, F	1
Sang, Y	1
Li, M	2
Li, Y	2
Zhao, J	1
Wei, Y	1
Fuentes, CF	1
Shapshay, SM	1
Lin, E	1
Morris, JS	1
Ayers, GD	1
Mohan, S	1
Epstein, JB	1
Choy, H	1
Milas, L	1
Ranelletti, FO	1
Lauriola, L	1
Salutari, V	1
Gessi, M	1
Testa, AC	1
Werner, U	1
Navarra, P	1
Tringali, G	1
Battaglia, A	1
Wei, D	1
He, Y	2
Xiong, HQ	1
Abbruzzese, JL	1
Xie, K	1
Roh, JL	1
Sung, MW	1
Park, SW	1
Heo, DS	1
Lee, DW	1
Kim, KH	1
Gupta, S	1
Adhami, VM	1
Subbarayan, M	1
MacLennan, GT	1
Lewin, JS	1
Hafeli, UO	1
Mukhtar, H	1
Gately, S	1
Li, WW	1
Chen, PY	1
Long, QC	1
Fu, SL	1
Wu, YL	1
Zhang, YP	1
Qiao, MM	1
Chen, Y	1
Prosperi, JR	1
Mallery, SR	1
Kigerl, KA	1
Erfurt, AA	1
Robertson, FM	1
Chu, AJ	1
Chou, TH	1
Chen, BD	1
Chen, Z	1
Zhang, X	1
Wieand, HS	1
Grandis, JR	1
Shin, DM	1
Merchan, JR	1
Jayaram, DR	1
Supko, JG	1
He, X	1
Bubley, GJ	1
Sukhatme, VP	1
Raut, CP	1
Nawrocki, S	1
Lashinger, LM	1
Davis, DW	1
Khanbolooki, S	1
Xiong, H	1
Ellis, LM	1
McConkey, DJ	1
Nishimura, N	1
Urade, M	1
Hashitani, S	1
Noguchi, K	1
Manno, Y	1
Takaoka, K	1
Sakurai, K	1
Collins, TS	1
Hurwitz, HI	1
Graepler, F	1
Gregor, M	1
Lauer, UM	1
Basu, GD	2
Pathangey, LB	1
Tinder, TL	1
Gendler, SJ	1
Mukherjee, P	2
Ferrario, A	1
Fisher, AM	1
Rucker, N	1
Gomer, CJ	1
Yee, KK	1
Soo, KC	1
Olivo, M	1
Hahn, T	1
Alvarez, I	1
Kobie, JJ	1
Ramanathapuram, L	1
Dial, S	1
Fulton, A	1
Besselsen, D	1
Walker, E	1
Akporiaye, ET	1
Zuo, CH	1
Li, ZR	1
Zhou, X	1
Ouyang, YZ	1
Zhou, ZY	1
Zeng, L	1
Grösch, S	1
Maier, TJ	1
Schiffmann, S	1
Geisslinger, G	1
Liang, WS	1
Stephan, DA	1
Wegener, LT	1
Conley, CR	1
Pockaj, BA	1
Zhou, Y	1
Ran, J	1
Tang, C	1
Honghua, L	1
Xingwen, L	1
Ning, C	1
Qiao, L	1
Kang, KB	1
Wang, TT	1
Woon, CT	1
Cheah, ES	1
Moore, XL	1
Zhu, C	1
Wong, MC	1
Fournier, LS	1
Novikov, V	1
Lucidi, V	1
Fu, Y	1
Miller, T	1
Floyd, E	1
Shames, DM	1
Brasch, RC	1
Irie, T	1
Tsujii, M	1
Tsuji, S	1
Yoshio, T	1
Ishii, S	1
Shinzaki, S	1
Egawa, S	1
Kakiuchi, Y	1
Nishida, T	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Anti-Angiogenic Chemotherapy: A Phase II Trial of the Oral 5-Drug Regimen (Thalidomide, Celecoxib, Fenofibrate, Etoposide and Cyclophosphamide) in Patients With Relapsed or Progressive Cancer[NCT00357500]	Phase 2	101 participants (Actual)	Interventional	2005-01-31	Completed
Phase II Study of the Combination Carboplatin Plus Celecoxib in Heavily Pre-treated Recurrent Ovarian Cancer Patients[NCT01124435]	Phase 2	45 participants (Actual)	Interventional	2003-10-31	Completed
Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine: A Randomized Controlled Trial.[NCT05641246]	Phase 2	66 participants (Anticipated)	Interventional	2022-12-08	Active, not recruiting
09.017 - A Phase I Study of Tolfenamic Acid With Gemcitabine and Radiation in Patients With Locally Advanced or Metastatic Pancreatic Cancer Requiring Definitive or Palliative Radiation Therapy[NCT02159248]	Phase 1	0 participants (Actual)	Interventional	2014-03-31	Withdrawn (stopped due to The study closed prior to enrolling any participants.)
IRB-HSR# 13957: IV Lidocaine for Patients Undergoing Primary Breast Cancer Surgery: Effects on Postoperative Recovery and Cancer Recurrence[NCT01204242]	Phase 2	78 participants (Actual)	Interventional	2009-08-01	Completed
Radiosensitization With a COX-2 Inhibitor (Celecoxib), With Chemoradiation for Cancer of the Head and Neck[NCT00581971]	Phase 1/Phase 2	30 participants (Actual)	Interventional	2002-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

27-week overall survival is the probability of patients remaining alive at 27-weeks from study entry estimated using with Kaplan-Meier methods. (NCT00357500)
Timeframe: Assessed every 9 weeks on treatment and annually until death or initiation of new therapy, up to 27 weeks.

27-Week Progression-Free Survival

Intervention	Probability (Number)
5-drug Metronomic Antiangiogenic Regimen	0.61

27-week progression-free survival is the probability of patients remaining alive and progression-free at 27-weeks from study entry estimated using Kaplan-Meier methods. As appropriate for tumor type and location, gadolinium-enhanced MRI and other imaging modalites were used to assess response. Progressive disease was defined as >/=25% increase in product of diameters, development of new areas of disease, or disease-attributable clinical deterioration or death, progressive disease. For patients with leukemia PD was defined as >/=25% or >/=5,000 cells/mm3 increase in number of circulating cells, development of extramedullary disease, or other clinical evidence of progression. (NCT00357500)
Timeframe: Assessed every 9 weeks on treatment and annually until death or initiation of new therapy, up to 27 weeks.

Therapy Completion Rate

Intervention	Probability (Number)
5-drug Metronomic Antiangiogenic Regimen	0.31

Proportion of patients alive at 27 weeks without progressive disease (PD) and having tolerated therapy. As appropriate for tumor type and location, gadolinium-enhanced MRI and other imaging modalites were used to assess response. Progressive disease was defined as >/=25% increase in product of diameters, development of new areas of disease, or disease-attributable clinical deterioration or death, progressive disease. For patients with leukemia PD was defined as >/=25% or >/=5,000 cells/mm3 increase in number of circulating cells, development of extramedullary disease, or other clinical evidence of progression. (NCT00357500)
Timeframe: 27 weeks

Best Response

Intervention	proportion of patients (Number)
5-drug Metronomic Antiangiogenic Regimen	.25

As appropriate for tumor type and location, gadolinium-enhanced MRI and other imaging modalites were used to assess response. Best response was regarded as best response at any single assessment. Response was defined as follows: complete resolution of all demonstrable tumor, complete response (CR); >/=50% decrease in the product of the 2 maximum perpendicular diameters relative to the baseline evaluation, partial response (PR); <50% decrease and <25% increase in product of diameters, stable disease (SD); and >/=25% increase in product of diameters, development of new areas of disease, or disease-attributable clinical deterioration or death, progressive disease (PD). For patients with leukemia PD was defined as >/=25% or >/=5,000 cells/mm3 increase in number of circulating cells, development of extramedullary disease, or other clinical evidence of progression. (NCT00357500)
Timeframe: Assessed at study entry, every 9 weeks on treatment and at treatment discontinuation, up to 27 weeks.

Response as Evaluated by Recurrence of Diseases

Intervention	participants (Number)
	Complete Response	Partial Response	Stable Disease	Progressive Disease	Not Evaluable
5-drug Metronomic Antiangiogenic Regimen	1	12	36	47	1

Evaluate the response to concurrent celecoxib, carboplatin, paclitaxel, and radiotherapy in the treatment of locally advanced SSC of the head and neck. Response is determined by local control only, local and distant metastasis, distant metastasis only, second primary, and surgical salvage. (NCT00581971)
Timeframe: 2 years from end of treatment (Radiation therapy)

Toxicity of Celecoxib With Concurrent Weekly Chemotherapy and Radiotherapy in the Treatment of Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck.

Intervention	Participants (Number)
	Local Control Only	Local Control and Distant Metastasis	Distant Metastatsis Only	Secondary Primary - Site Unknown	Surgical Salvage
Recurrence	6	2	1	2	3

Particpants experiencing Acute Toxicities > Grade 3 (NCT00581971)
Timeframe: 2 years from radiation therapy

Intervention	participants (Number)
	Hematologic	Dermatitis	Mucositis/Dysphagia
Acute Toxicity	12	7	16

Article	Year
Emerging opportunities for the combination of molecularly targeted drugs with radiotherapy. Clinical oncology (Royal College of Radiologists (Great Britain)), 2014, Volume: 26, Issue:5 Topics: Antineoplastic Agents; Celecoxib; Chemoradiotherapy; Clinical Trials as Topic; Cyclooxygenase 2 Inhi	2014
Carcinogenesis and cyclooxygenase: the potential role of COX-2 inhibition in upper aerodigestive tract cancer. Oral oncology, 2003, Volume: 39, Issue:6 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous	2003
Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? Journal of the National Cancer Institute, 2003, Oct-01, Volume: 95, Issue:19 Topics: Animals; Antineoplastic Agents; Apoptosis; Celecoxib; Chemotherapy, Adjuvant; Clinical Trials as Top	2003
Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Seminars in oncology, 2004, Volume: 31, Issue:2 Suppl 7 Topics: Angiogenesis Inhibitors; Animals; Anticarcinogenic Agents; Celecoxib; Cell Movement; Cyclooxygenase	2004
Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications. Frontiers in bioscience : a journal and virtual library, 2004, Sep-01, Volume: 9 Topics: Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Carcinogens	2004
Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. Seminars in oncology, 2005, Volume: 32, Issue:1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Cel	2005
[Anti-angiogenic therapy for gastrointestinal tumours]. Zeitschrift fur Gastroenterologie, 2005, Volume: 43, Issue:3 Topics: Adult; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized;	2005
Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. Journal of the National Cancer Institute, 2006, Jun-07, Volume: 98, Issue:11 Topics: Adenomatous Polyposis Coli; Adenomatous Polyposis Coli Protein; Animals; Anti-Inflammatory Agents, N	2006
Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs. Expert opinion on investigational drugs, 2008, Volume: 17, Issue:2 Topics: Animals; Antineoplastic Agents; Celecoxib; Cyclooxygenase 2; Drug Evaluation, Preclinical; Humans; N	2008

Article	Year
A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatric blood & cancer, 2014, Volume: 61, Issue:4 Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Celecoxi	2014
[Celecoxib induces apoptosis and inhibits angiogenesis in gastric cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2008, Volume: 30, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Apoptosis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Fe	2008
Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions. World journal of gastroenterology, 2009, Jun-14, Volume: 15, Issue:22 Topics: Adult; Aged; Apoptosis; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors	2009
Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients. BMC cancer, 2011, May-31, Volume: 11 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cel	2011
Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Oct-01, Volume: 9, Issue:12 Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antigens, Neoplasm; Apoptosis; Blood Vessels; Carcinoma, Sq	2003
Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition. International journal of cancer, 2005, Jan-20, Volume: 113, Issue:3 Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pro	2005
Effect of celecoxib on E-cadherin, VEGF, Microvessel density and apoptosis in gastric cancer. Cancer biology & therapy, 2007, Volume: 6, Issue:2 Topics: Adult; Aged; Apoptosis; Cadherins; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Female; H	2007
Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro-oncology, 2007, Volume: 9, Issue:3 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasm	2007
Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study. Onkologie, 2007, Volume: 30, Issue:12 Topics: Administration, Oral; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Capec	2007
Biologic markers of angiogenesis: circulating endothelial cells in patients with advanced malignancies treated on phase I protocol with metronomic chemotherapy and celecoxib. Cancer investigation, 2008, Volume: 26, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Celecoxib; Cyclophos	2008

Article	Year
Predicting new indications for approved drugs using a proteochemometric method. Journal of medicinal chemistry, 2012, Aug-09, Volume: 55, Issue:15 Topics: Animals; Antineoplastic Agents; Antirheumatic Agents; Cadherins; Celecoxib; Cell Line, Tumor; Crysta	2012
The effect of celecoxib in traumatic heterotopic ossification around temporomandibular joint in mice. Osteoarthritis and cartilage, 2020, Volume: 28, Issue:4 Topics: Animals; Bone Morphogenetic Protein Receptors, Type I; Cartilage, Articular; Celecoxib; Cell Differe	2020
Quercetin Downregulates Cyclooxygenase-2 Expression and HIF-1 BioMed research international, 2020, Volume: 2020 Topics: Angiogenesis Inhibitors; Animals; Aortic Aneurysm, Abdominal; Celecoxib; Cyclooxygenase 2 Inhibitors	2020
Synergistic effect of bevacizumab and celecoxib on angiogenesis in vitro using human umbilical vein endothelial cells. International journal of clinical pharmacology and therapeutics, 2020, Volume: 58, Issue:12 Topics: Angiogenesis Inhibitors; Bevacizumab; Celecoxib; Cell Movement; Cell Proliferation; Human Umbilical	2020
Celecoxib normalizes the tumor microenvironment and enhances small nanotherapeutics delivery to A549 tumors in nude mice. Scientific reports, 2017, 08-30, Volume: 7, Issue:1 Topics: A549 Cells; Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents, Phytogenic; Celecox	2017
The effectiveness of cyclooxygenase-2 inhibitors and evaluation of angiogenesis in the model of experimental colorectal cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, Volume: 102 Topics: 1,2-Dimethylhydrazine; Animals; Apoptosis; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibit	2018
Combinational Treatment Effect of Tetrahydrocurcumin and Celecoxib on Cervical Cancer Cell-Induced Tumor Growth and Tumor Angiogenesis in Nude Mice. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2016, Volume: 99 Suppl 4 Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Celecoxib; Combined Modality Therapy; Curcumin; Cycloox	2016
Caffeic acid and ellagic acid ameliorate adjuvant-induced arthritis in rats via targeting inflammatory signals, chitinase-3-like protein-1 and angiogenesis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2019, Volume: 110 Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Caffeic Acids; Celecoxib; Chitinase-3-Li	2019
A practical and sensitive method of quantitating lymphangiogenesis in vivo. Laboratory investigation; a journal of technical methods and pathology, 2013, Volume: 93, Issue:7 Topics: Angiogenesis Inhibitors; Animals; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 In	2013
Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling. BMC cancer, 2013, Jun-03, Volume: 13 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autocrine Communication; Blotting, Western;	2013
Celecoxib ameliorates portal hypertension of the cirrhotic rats through the dual inhibitory effects on the intrahepatic fibrosis and angiogenesis. PloS one, 2013, Volume: 8, Issue:7 Topics: Angiogenesis Inhibitors; Animals; Celecoxib; Disease Models, Animal; Hypertension, Portal; Kidney; L	2013
Roles of microsomal prostaglandin E synthase-1 in lung metastasis formation in prostate cancer RM9 cells. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2014, Volume: 68, Issue:1 Topics: Animals; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Down-Regulation; Gene Expression	2014
Antitumor effect of a selective COX-2 inhibitor, celecoxib, may be attributed to angiogenesis inhibition through modulating the PTEN/PI3K/Akt/HIF-1 pathway in an H₂₂ murine hepatocarcinoma model. Oncology reports, 2014, Volume: 31, Issue:5 Topics: Animals; Antigens, CD34; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Celecoxib; Cell	2014
COX-2 overexpression increases malignant potential of human glioma cells through Id1. Oncotarget, 2014, Mar-15, Volume: 5, Issue:5 Topics: Animals; Celecoxib; Cell Line, Tumor; Cell Transformation, Neoplastic; Cyclooxygenase 2; Cyclooxygen	2014
Evening primrose oil and celecoxib inhibited pathological angiogenesis, inflammation, and oxidative stress in adjuvant-induced arthritis: novel role of angiopoietin-1. Inflammopharmacology, 2014, Volume: 22, Issue:5 Topics: Administration, Oral; Angiopoietin-1; Animals; Anti-Inflammatory Agents; Antioxidants; Arthritis, Ex	2014
Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer. Biomaterials, 2014, Volume: 35, Issue:26 Topics: Animals; Antineoplastic Agents; Apoptosis; Breast; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Dr	2014
Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions. Cancer science, 2014, Volume: 105, Issue:9 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Celecoxib; Cell Line, Tumor;	2014
Combinational chemoprevention effect of celecoxib and an oral antiangiogenic LHD4 on colorectal carcinogenesis in mice. Anti-cancer drugs, 2014, Volume: 25, Issue:9 Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Anticarcinogenic Agents; Azoxymethane; Carci	2014
Celecoxib decreases growth and angiogenesis and promotes apoptosis in a tumor cell line resistant to chemotherapy. Biological research, 2014, Jun-16, Volume: 47 Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Breast Neoplas	2014
Enhanced Anti-Angiogenic Effect of Low Molecular Weight Heparin-Bile Acid Conjugates by Co-Administration of a Selective COX-2 Inhibitor. Pharmaceutical research, 2015, Volume: 32, Issue:7 Topics: Angiogenesis Inhibitors; Animals; Celecoxib; Cell Hypoxia; Cyclooxygenase 2; Cyclooxygenase 2 Inhibi	2015
Lipopolysaccharide induces inflammation and facilitates lung metastasis in a breast cancer model via the prostaglandin E2-EP2 pathway. Molecular medicine reports, 2015, Volume: 11, Issue:6 Topics: Animals; Blood Vessels; Breast Neoplasms; Celecoxib; Cell Proliferation; Cells, Cultured; Cyclooxyge	2015
Reducing tumor growth and angiogenesis using a triple therapy measured with Contrast-enhanced ultrasound (CEUS). BMC cancer, 2015, May-08, Volume: 15 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cell Line, Tumor; Cell Prolifera	2015
Simultaneous inhibition of EGFR/VEGFR and cyclooxygenase-2 targets stemness-related pathways in colorectal cancer cells. PloS one, 2015, Volume: 10, Issue:6 Topics: Apoptosis; Caco-2 Cells; Celecoxib; Cell Cycle; Cell Proliferation; Colorectal Neoplasms; Cyclooxyge	2015
Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard Treatment. Anticancer research, 2015, Volume: 35, Issue:9 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Che	2015
Celecoxib and octreotide synergistically ameliorate portal hypertension via inhibition of angiogenesis in cirrhotic rats. Angiogenesis, 2016, Volume: 19, Issue:4 Topics: Angiogenesis Inhibitors; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Synergism; Hypertensi	2016
Expression of Endoglin and Vascular Endothelial Growth Factor as Prognostic Markers in Experimental Colorectal Cancer. Anticancer research, 2016, Volume: 36, Issue:8 Topics: Adenocarcinoma; Animals; Biomarkers, Tumor; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibi	2016
Chemoprevention of Colon Cancer through Inhibition of Angiogenesis and Induction of Apoptosis by Nonsteroidal Anti-Inflammatory Drugs. Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer, 2016, Volume: 35, Issue:3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Apoptosis; Celecoxib; Col	2016
Metastatic hepatic epithelioid hemangioendothelioma in a teenage girl. Journal of pediatric hematology/oncology, 2008, Volume: 30, Issue:7 Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Ce	2008
The human cytomegalovirus-encoded chemokine receptor US28 promotes angiogenesis and tumor formation via cyclooxygenase-2. Cancer research, 2009, Apr-01, Volume: 69, Issue:7 Topics: Animals; Celecoxib; Cell Line; Cell Transformation, Viral; Cyclooxygenase 2; Cyclooxygenase 2 Inhibi	2009
Synergistic inhibition effect of tumor growth by using celecoxib in combination with oxaliplatin. Cancer investigation, 2009, Volume: 27, Issue:6 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Catenin; Celecoxib; Cell Pr	2009
First experiences with low-dose anti-angiogenic treatment in gliomatosis cerebri with signs of angiogenic activity. Anticancer research, 2009, Volume: 29, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cell Proliferation; Cyclooxy	2009
Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model. Cancer letters, 2010, Feb-28, Volume: 288, Issue:2 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain N	2010
Celecoxib treatment reduces peritoneal fibrosis and angiogenesis and prevents ultrafiltration failure in experimental peritoneal dialysis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2009, Volume: 24, Issue:12 Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Hemodiafiltration; Male; Neovascularization, Pathol	2009
Recruited bone marrow cells expressing the EP3 prostaglandin E receptor subtype enhance angiogenesis during chronic inflammation. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2010, Volume: 64, Issue:2 Topics: Animals; Bone Marrow Cells; Bone Marrow Transplantation; Celecoxib; Cyclooxygenase 2; Cyclooxygenase	2010
Vascular endothelial growth factor and not cyclooxygenase 2 promotes endothelial cell viability in the pancreatic tumor microenvironment. Pancreas, 2010, Volume: 39, Issue:5 Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cell Survival; Cyclooxy	2010
Celecoxib can induce vascular endothelial growth factor expression and tumor angiogenesis. Molecular cancer therapeutics, 2011, Volume: 10, Issue:1 Topics: Animals; Celecoxib; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Cyclooxygenase 2 Inhibitors; Endo	2011
Celecoxib enhances radiation response of secondary bone tumors of a human non-small cell lung cancer via antiangiogenesis in vivo. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2011, Volume: 187, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Di	2011
Selective inhibition of cyclooxygenase-2 suppresses metastatic disease without affecting primary tumor growth in a murine model of Ewing sarcoma. Journal of pediatric surgery, 2011, Volume: 46, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 In	2011
Chemoprevention: First line of defence. Nature, 2011, Mar-24, Volume: 471, Issue:7339 Topics: Animals; Aspirin; Celecoxib; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Cyclooxygenase I	2011
Regression of prostate tumors upon combination of hormone ablation therapy and celecoxib in vivo. The Prostate, 2011, Jun-01, Volume: 71, Issue:8 Topics: Androgen Antagonists; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Hormonal; Celecoxib;	2011
The inhibitory effect of celecoxib and rosiglitazone on experimental endometriosis. Fertility and sterility, 2011, Volume: 96, Issue:2 Topics: Analysis of Variance; Animals; Antigens, CD34; Apoptosis; Celecoxib; Cell Proliferation; Cyclooxygen	2011
Antiangiogenic treatment as a pre-operative management of alveolar soft-part sarcoma. Pediatric blood & cancer, 2011, Dec-01, Volume: 57, Issue:6 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Celecoxib; Child, Preschool	2011
Transgenic insulin-like growth factor-1 stimulates activation of COX-2 signaling in mammary glands. Molecular carcinogenesis, 2012, Volume: 51, Issue:12 Topics: Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Enzyme Activation; Enzyme-Linked	2012
[Immunomodulation and antiangiogenesis in cancer therapy. From basic to clinical research]. Medicina, 2012, Volume: 72, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Breast Neoplasms; Celecoxib; Cl	2012
Role of Sulindac and Celecoxib in the regulation of angiogenesis during the early neoplasm of colon: exploring PI3-K/PTEN/Akt pathway to the canonical Wnt/β-catenin signaling. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2012, Volume: 66, Issue:5 Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Blotting, West	2012
Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum. Oncology reports, 2012, Volume: 28, Issue:3 Topics: Animals; Antineoplastic Agents; Apoptosis; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2; Cycloo	2012
Primary tumor regulates the pulmonary microenvironment in melanoma carcinoma model and facilitates lung metastasis. Journal of cancer research and clinical oncology, 2013, Volume: 139, Issue:1 Topics: Animals; Biomarkers, Tumor; Celecoxib; Cyclooxygenase 2 Inhibitors; Cytokines; Female; Inflammation;	2013
Transcatheter arterial embolization followed by octreotide and celecoxib synergistically prolongs survival of rabbits with hepatic VX2 allografts. Journal of digestive diseases, 2013, Volume: 14, Issue:1 Topics: Abdominal Neoplasms; Analysis of Variance; Animals; Antineoplastic Combined Chemotherapy Protocols;	2013
Celecoxib enhances the efficacy of 15-hydroxyprostaglandin dehydrogenase gene therapy in treating murine breast cancer. Journal of cancer research and clinical oncology, 2013, Volume: 139, Issue:5 Topics: Animals; Apoptosis; Celecoxib; Cell Line, Tumor; Combined Modality Therapy; Cyclooxygenase 2; Cycloo	2013
Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell. The Laryngoscope, 2002, Volume: 112, Issue:5 Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Carcinoma, Squamous Cell; Celecoxib; Cell Di	2002
Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:12 Suppl N Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Capecitabine; Celecoxib; Colorectal Neoplasms;	2002
Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer research, 2004, Mar-15, Volume: 64, Issue:6 Topics: Adenocarcinoma; Animals; Celecoxib; Cyclooxygenase Inhibitors; Electrophoretic Mobility Shift Assay;	2004
Celecoxib can prevent tumor growth and distant metastasis in postoperative setting. Cancer research, 2004, May-01, Volume: 64, Issue:9 Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Celecoxib; Cell Division; Cell Line, Tumor	2004
Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer research, 2004, May-01, Volume: 64, Issue:9 Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Biomarkers, Tumor; Celecoxib; Cell Division; Cyclo	2004
Effects of cyclooxygenase 2 inhibitors on biological traits of nasopharyngeal carcinoma cells. Acta pharmacologica Sinica, 2004, Volume: 25, Issue:7 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Celeco	2004
Anti-cancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer. World journal of gastroenterology, 2004, Jul-01, Volume: 10, Issue:13 Topics: Animals; Apoptosis; Celecoxib; Cell Division; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 I	2004
Invasive and angiogenic phenotype of MCF-7 human breast tumor cells expressing human cyclooxygenase-2. Prostaglandins & other lipid mediators, 2004, Volume: 73, Issue:3-4 Topics: Breast Neoplasms; Celecoxib; Cell Line, Tumor; Cell Proliferation; Clone Cells; Collagen; Cyclooxyge	2004
Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Sep-01, Volume: 10, Issue:17 Topics: Angiogenesis Inhibitors; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Cycle; Cyclooxygenase	2004
Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts. Cancer biology & therapy, 2004, Volume: 3, Issue:12 Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Celecoxib; Cyclooxygena	2004
Increased expression of cyclooxygenase (COX)-2 in DMBA-induced hamster cheek pouch carcinogenesis and chemopreventive effect of a selective COX-2 inhibitor celecoxib. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2004, Volume: 33, Issue:10 Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; C	2004
Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast cancer research : BCR, 2005, Volume: 7, Issue:4 Topics: Animals; Breast Neoplasms; Celecoxib; Cell Cycle; Cell Proliferation; Cyclooxygenase 2; Cyclooxygena	2005
Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors. Cancer research, 2005, Oct-15, Volume: 65, Issue:20 Topics: Animals; Apoptosis; Celecoxib; Cyclooxygenase Inhibitors; Dihematoporphyrin Ether; Dinoprostone; Dru	2005
Anti-angiogenic effects of Hypericin-photodynamic therapy in combination with Celebrex in the treatment of human nasopharyngeal carcinoma. International journal of molecular medicine, 2005, Volume: 16, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Anthracenes; Celecoxib; Cyclooxygenase 2; Drug Therapy, Combinatio	2005
Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer. International journal of cancer, 2006, May-01, Volume: 118, Issue:9 Topics: Administration, Oral; Animals; Breast Neoplasms; Cancer Vaccines; CD4-Positive T-Lymphocytes; CD8-Po	2006
The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice. BMC cancer, 2006, Jan-12, Volume: 6 Topics: Animals; Bone Neoplasms; Celecoxib; Cell Line, Tumor; Cyclooxygenase Inhibitors; Lung Neoplasms; Mal	2006
[Inhibitory effects of cyclooxygenase-2 inhibitor celecoxib on growth and angiogenesis of human liver cancer HepG2 cell xenografts in small nude mice]. Ai zheng = Aizheng = Chinese journal of cancer, 2006, Volume: 25, Issue:4 Topics: Angiopoietin-2; Animals; Carcinoma, Hepatocellular; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; C	2006
A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells. Breast cancer research : BCR, 2006, Volume: 8, Issue:6 Topics: Animals; Blood Vessels; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygen	2006
Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis. International journal of radiation oncology, biology, physics, 2007, Mar-01, Volume: 67, Issue:3 Topics: Angiopoietin-1; Angiopoietin-2; Animals; Brain Neoplasms; Celecoxib; Cell Line, Tumor; Combined Moda	2007
MR monitoring of cyclooxygenase-2 inhibition of angiogenesis in a human breast cancer model in rats. Radiology, 2007, Volume: 243, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Contrast Media; Cyc	2007
Synergistic antitumor effects of celecoxib with 5-fluorouracil depend on IFN-gamma. International journal of cancer, 2007, Aug-15, Volume: 121, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colonic Neoplasms; Cyclooxygenas	2007
COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. British journal of cancer, 2007, Dec-03, Volume: 97, Issue:11 Topics: Analgesia; Analgesics, Opioid; Analysis of Variance; Animals; Behavior, Animal; Blotting, Western; C	2007
Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer. Experimental oncology, 2008, Volume: 30, Issue:1 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Celecoxib; Cell Proliferation; Colonic Ne	2008
Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer research, 2000, Mar-01, Volume: 60, Issue:5 Topics: Animals; Anticarcinogenic Agents; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxy	2000
Characterization of the effects of antiangiogenic agents on tumor pathophysiology. American journal of clinical oncology, 2001, Volume: 24, Issue:5 Topics: Angiogenesis Inhibitors; Animals; Celecoxib; Cell Hypoxia; Cyclooxygenase 2; Cyclooxygenase 2 Inhibi	2001
Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer research, 2002, Feb-01, Volume: 62, Issue:3 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Celecoxib; Cell Division; Coloni	2002

celecoxib and Angiogenesis, Pathologic